# ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

> **NCT05653271** · PHASE1 · RECRUITING · sponsor: **Acepodia Biotech, Inc.** · enrollment: 42 (estimated)

## Conditions studied

- B-cell Lymphoma
- Non Hodgkin Lymphoma
- DLBCL
- Primary Mediastinal Large B Cell Lymphoma
- Marginal Zone Lymphoma
- Follicular Lymphoma
- Burkitt Lymphoma
- High-grade B-cell Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** ACE1831
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT05653271
- **Lead sponsor:** Acepodia Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-21
- **Primary completion:** 2025-09
- **Final completion:** 2027-09
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05653271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05653271, "ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05653271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*